This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients. In a cross-over design, patients will be randomized to receive either a single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated time on study is up to approximately 9 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
19
Unnamed facility
Los Ageles, California, United States
Unnamed facility
New Haven, Connecticut, United States
Unnamed facility
The Bronx, New York, United States
Efficacy: Behavior assessments
Time frame: up to 24 hours post-dose
Safety: Incidence of adverse events
Time frame: up to 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.